From the Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (Mihalache, Huang); Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada (Popovic, Muni); Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada (Muni).

Corresponding author: Rajeev H. Muni, MD, MSc, FRCSC, Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, 30 Bond St, Donnelly Wing, 8th Floor, Toronto, ON M5B 1W8, Canada. Email: [email protected].

Disclosures: M.M. Popovic: financial support (to institution): PSI Foundation, Fighting Blindness Canada. R.H. Muni: consultant: Alcon Laboratories, Inc., Apellis, AbbVie, Bayer Healthcare AG, Bausch Health Companies, Inc., Roche Innovatis AG; financial support (to institution): Alcon Laboratories, Inc., AbbVie, Bayer Healthcare AG, Novartis Corp., Roche Innovatis AG. None of the other authors has any financial or proprietary interest in any material or method mentioned. We thank the American Academy of Ophthalmology for courteously allowing us to compare outputs generated by an artificial intelligence chatbot to information present in the Academy Preferred Practice Pattern® Guidelines.

First author:Andrew Mihalache, MD(C)Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada